$253 Million

Repare Therapeutics

Initial Public Offering

Bookrunner, June 2020

Repare Therapeutics Inc. is a precision medicine oncology company focused on bringing novel synthetic lethality based therapies to patients with cancer. The Company applies its proprietary genome-wide, CRISPR-enabled platform, SNIPRx, to systematically discover and develop highly targeted cancer therapies focused on genome instability, including DNA damage repair. The platform is built on three primary pillars: identifying both known and unknown SL targets using proprietary genetic screening technology, designing and synthesizing potent and selective small molecule inhibitors of these targets and expanding beyond the initial target population. The Company’s lead product candidate, RP-3500, is a potent and selective inhibitor of ATR, or ataxia telangiectasia and Rad3-related protein, that is being developed for the treatment of tumors with mutations in ATM, or ataxia-telangiectasia mutated kinase, which is an SL pair with ATR.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details